I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Table3_Ocular adverse events associated with anti-VEGF ther..:
Pan Ma
;
Xinmei Pan
;
Ruixiang Liu
...
doi:10.3389/fphar.2022.1017889.s001. , 2022
Link:
https://doi.org/10.3389/fphar.2022.1017889.s001
RT Journal T1
Table3_Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS).DOCX
UL https://suche.suub.uni-bremen.de/peid=base-ftfrontimediafig:oai:figshare.com:article_21580362&Exemplar=1&LAN=DE A1 Pan Ma A1 Xinmei Pan A1 Ruixiang Liu A1 Ya Qu A1 Linli Xie A1 Jiangchuan Xie A1 Liya Cao A1 Yongchuan Chen YR 2022 K1 Pharmacology K1 Basic Pharmacology K1 Clinical Pharmacology and Therapeutics K1 Clinical Pharmacy and Pharmacy Practice K1 Pharmaceutical Sciences K1 Pharmacogenomics K1 Toxicology (incl. Clinical Toxicology) K1 Pharmacology and Pharmaceutical Sciences not elsewhere classified K1 adverse events K1 pharmacovigilance K1 ranibizumab K1 aflibercept K1 brolucizumab K1 safety signals JF doi:10.3389/fphar.2022.1017889.s001 LK http://dx.doi.org/https://doi.org/10.3389/fphar.2022.1017889.s001 DO https://doi.org/10.3389/fphar.2022.1017889.s001 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)